Information deficits in the summary of product characteristics preclude an optimal management of drug interactions: A comparison with evidence from the literature

European Journal of Clinical Pharmacology

Volumn 61, Issue 5-6, 2005, Pages 327-335

  Bergk, Verena ^a   Haefeli, Walter E ^a   Gasse, Christiane ^a   Brenner, Hermann ^b   Martin Facklam, Meret ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CENTRE FOR RESEARCH ON AGEING   (Germany)

Author keywords

Drug interactions; Drug labelling; Summary of product characteristics

Indexed keywords

AMIODARONE; AMITRIPTYLINE; ATORVASTATIN; CARBAMAZEPINE; CLOZAPINE; CYCLOSPORIN; DIGOXIN; DILTIAZEM; FENOFIBRATE; FLUINDOSTATIN; FLUOXETINE; LITHIUM; METHADONE; METHOTREXATE; METOPROLOL; PHENOBARBITAL; PHENPROCOUMON; PHENYTOIN; PRAVASTATIN; QUINIDINE; SIMVASTATIN; TERFENADINE; THEOPHYLLINE; VALPROIC ACID; WARFARIN;

AREA UNDER THE CURVE; ARRHYTHMOGENESIS; ARTICLE; BLEEDING; CYTOTOXICITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG INFORMATION; DRUG LABELING; DRUG MARKETING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; HUMAN; PRESCRIPTION; PRIORITY JOURNAL; QT PROLONGATION; QUESTIONNAIRE; RHABDOMYOLYSIS;

DATABASES; DRUG INFORMATION SERVICES; DRUG INTERACTIONS; DRUG LABELING; GERMANY; MEDICAL INFORMATICS; RESEARCH DESIGN;

EID: 27644511324     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-005-0943-4     Document Type: Article

References (26)

1. Veehof LJG, Stewart RE, Haaijer-Ruskamp FM, Meyboom-de Jong B (2000) The development of polypharmacy. A longitudinal study. Fam Pract 17:261-267
2. Rosholm JU, Bjerrum L, Hallas J, Worm J, Gram LF (1998) Polypharmacy and the risk of drug-drug interactions among Danish elderly. Dan Med Bull 45:210-213
3. Bergk V, Gasse C, Rothenbacher D, Loew M, Brenner H, Haefeli WE (2004) Drug interactions in primary care: impact of a new algorithm on risk determination. Clin Pharmacol Ther 76:85-96
4. Bergk V, Gasse C, Schnell R, Haefeli WE (2004) Requirements for a successful implementation of drug interaction information systems in general practice: results of a questionnaire survey in Germany. Eur J Clin Pharmacol 60:595-602
5. Rawlins MD (1996) The clinical pharmacologist in drug regulation: a European perspective. Br J Clin Pharmacol 42:59-61
6. Rajpal A, Reidenberg MM (2003) Drug labeling should be kept current. Clin Pharmacol Ther 73:4-6
7. Mullen WH, Anderson IB, Kim SY, Blanc PD, Olson KR (1997) Incorrect overdose management advice in the Physicians' Desk Reference. Ann Emerg Med 29:255-261
8. Spyker DA, Harvey ED, Harvey BE, Harvey AM, Rumack BH, Peck CC, Atkinson AJ Jr, Woosley RL, Abernethy DR, Cantilena LR (2000) Assessment and reporting of clinical pharmacology information in drug labeling. Clin Pharmacol Ther 67:196-200
9. Cohen JS (2001) Dose discrepancies between the Physicians' Desk Reference and the medical literature, and their possible role in the high incidence of dose-related adverse drug events. Arch Intern Med 161:957-964
10. European Commission (2004) Notice to applicants. A guideline on summary of product characteristics (EC). Available from: URL:http://pharmacos.eudra.org/ F2/eudralex/vol-2/C/SPC-GuidRev0-Dec99.pdf. Accessed May 19, 2004
11. Marroum PJ, Gobburu J (2002) The product label: how pharmacokinetics and pharmacodynamics reach the prescriber. Clin Pharmacokinet 41:161-169
12. Aronson JK (2004) Drug interactions-information, education, and the British National Formulary. Br J Clin Pharmacol 57:371-372
13. Anonymous (2001) Failings in treatment advice, SPCs and black triangles. Drug Ther Bull 39:25-27
14. Martin-Facklam M, Rengelshausen J, Tayrouz Y, Ketabi-Kiyanvash N, Lindenmaier H, Schneider V, Bergk V, Haefeli WE (2005) Dose individualisation in patients with renal insufficiency: does drug labelling support optimal management? Eur J Clin Pharmacol 60:807-811
15. Klasko RK (ed) (2003) DRUGDEX System. MICROMEDEX Inc. Greenwood Village, Colorado, version used: first quarter 2003
16. Stockley IH (2002) Stockley's drug interactions. The Pharmaceutical Press, London
17. Hansten PD, Horn JR (2003) Drug interactions analysis and management. Facts and Comparisons, St. Louis
18. Fachinformationsverzeichnis Deutschland (einschließlich EU-Zulassungen) (2003) BPI Service GmbH, Frankfurt, Germany, version used: first quarter 2003
19. Lin JC, Ito MK, Stolley SN, Morreale AP, Marcus DB (1999) The effect of converting from pravastatin to simvastatin on the pharmacodynamics of warfarin. J Clin Pharmacol 39:86-90
20. Pan HY (1991) Clinical pharmacology of pravastatin, a selective inhibitor of HMG-CoA reductase. Eur J Clin Pharmacol 40[Suppl 1]:S15-S18
21. McColl A, Smith H, White P, Field J (1998) General practitioner's perceptions of the route to evidence based medicine: a questionnaire survey. BMJ 316:361-365
22. Prosser H, Almond S, Walley T (2003) Influences on GPs' decision to prescribe new drugs-the importance of who says what. Fam Pract 20:61-68
23. Sjöqvist F (1997) A new classification system for drug interactions. Eur J Clin Pharmacol 52[Suppl 1]:A126
24. Fachinformationsverzeichnis Deutschland (einschließlich EU-Zulassungen). (2004) BPI Service GmbH, Frankfurt, Germany. Available from: URL:http://www.fachinfo.de. Accessed December 15, 2004
25. Reggi V, Balocco-Mattavelli R, Bonati M, Breton I, Figueras A, Jambert E, Kopp C, Montane E, Rago L, Rocchi F; The International Comparative Study on Drug Information Collaborative Group (2003) Prescribing information in 26 countries: a comparative study. Eur J Clin Pharmacol 59:263-270
26. McInnes GT, Brodie MJ (1988) Drug interactions that matter. A critical reappraisal. Drugs 36:83-110